Immunovant, Inc.

NasdaqGS:IMVT Stock Report

Market Cap: US$3.6b

Immunovant Management

Management criteria checks 3/4

Immunovant's CEO is Pete Salzmann, appointed in Dec 2019, has a tenure of 5.17 years. total yearly compensation is $8.55M, comprised of 8.2% salary and 91.8% bonuses, including company stock and options. directly owns 0.27% of the company’s shares, worth $9.69M. The average tenure of the management team and the board of directors is 3.3 years and 5.2 years respectively.

Key information

Pete Salzmann

Chief executive officer

US$8.6m

Total compensation

CEO salary percentage8.2%
CEO tenure5.2yrs
CEO ownership0.3%
Management average tenure3.3yrs
Board average tenure5.2yrs

Recent management updates

Recent updates

Immunovant: Continued FcRn Targeting With IMVT-1402 Pivotal Study

Dec 27

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Oct 16
Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Immunovant: Switching Lead Candidates Increases Risk

Oct 14

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Jul 18
We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Immunovant: Next Generation Anti-FcRn Candidate Keeps Hopes Alive

Jun 27

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Apr 19
We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)

Apr 04

Immunovant: An Intriguing And Developing Story

Jan 25

Immunovant, Inc. (NASDAQ:IMVT) Shares Could Be 33% Below Their Intrinsic Value Estimate

Jan 12
Immunovant, Inc. (NASDAQ:IMVT) Shares Could Be 33% Below Their Intrinsic Value Estimate

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Sep 28
We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Jun 14
Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Mar 08
Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Nov 06
We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Immunovant: Capitalizing On Fast Growing FcRn Space With Novel Asset

Oct 17

Immunovant stock down on raising $75M though equity capital

Oct 04

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Aug 06
We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Apr 06
Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Jun 20
We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Immunovant EPS beats by $0.04

Jun 01

argenx rise even as Immunovant pauses the trial for anti-FcRn therapy

Feb 03

Immunovant slips 7% on voluntary hold of IMVT-1401 dosing

Feb 02

Immunovant: IMVT-1401's Indication Expansion, $444M In Cash And New Management

Jan 14

Have Insiders Been Buying Immunovant, Inc. (NASDAQ:IMVT) Shares?

Dec 30
Have Insiders Been Buying Immunovant, Inc. (NASDAQ:IMVT) Shares?

Immunovant (IMVT) Investor Presentation - Slideshow

Nov 16

CEO Compensation Analysis

How has Pete Salzmann's remuneration changed compared to Immunovant's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$323m

Jun 30 2024n/an/a

-US$273m

Mar 31 2024US$9mUS$700k

-US$259m

Dec 31 2023n/an/a

-US$243m

Sep 30 2023n/an/a

-US$255m

Jun 30 2023n/an/a

-US$245m

Mar 31 2023US$6mUS$625k

-US$211m

Dec 31 2022n/an/a

-US$199m

Sep 30 2022n/an/a

-US$177m

Jun 30 2022n/an/a

-US$167m

Mar 31 2022US$6mUS$600k

-US$157m

Dec 31 2021n/an/a

-US$138m

Sep 30 2021n/an/a

-US$128m

Jun 30 2021n/an/a

-US$111m

Mar 31 2021US$15mUS$567k

-US$107m

Dec 31 2020n/an/a

-US$100m

Sep 30 2020n/an/a

-US$79m

Jun 30 2020n/an/a

-US$73m

Mar 31 2020US$9mUS$361k

-US$66m

Compensation vs Market: Pete's total compensation ($USD8.55M) is about average for companies of similar size in the US market ($USD6.61M).

Compensation vs Earnings: Pete's compensation has increased whilst the company is unprofitable.

CEO

Pete Salzmann (55 yo)

5.2yrs

Tenure

US$8,552,430

Compensation

Dr. Peter Salzmann, also known as Pete, M.D., M.B.A. is the Chief Executive Officer and Director of Immunovant, Inc. since December 2019. Dr. Salzmann has served as a member of Immunovant Sciences Ltd.’s b...

Leadership Team

NamePositionTenureCompensationOwnership
Frank Torti
Executive Chairperson of the Board5.2yrsUS$3.69m0.012%
$ 418.3k
Peter Salzmann
CEO & Director5.2yrsUS$8.55m0.27%
$ 9.7m
Jay Stout
Chief Technology Officer1.8yrsUS$4.04mno data
Eva Barnett
Chief Financial Officer3.3yrsUS$2.07m0.085%
$ 3.0m
Melanie Gloria
Chief Operating Officerless than a yearno datano data
Christopher Van Tuyl
Chief Legal Officer & Corporate Secretaryless than a yearno datano data
Lauren Schrier
Vice President of Marketing5.1yrsno datano data
Christine Blodgett
Senior Vice President of Human Resourcesno datano datano data
William Macias
Chief Medical Officer3.7yrsUS$1.92m0.12%
$ 4.3m
Andy Deig
Senior Vice President of Strategic Financeno datano datano data
Michael Geffner
Chief Medical Officer1.1yrsno data0.016%
$ 571.7k
Julie Kirschling
Senior Vice President of Program & Alliance Managementno datano datano data

3.3yrs

Average Tenure

51.5yo

Average Age

Experienced Management: IMVT's management team is considered experienced (3.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Frank Torti
Executive Chairperson of the Board5.2yrsUS$3.69m0.012%
$ 418.3k
Peter Salzmann
CEO & Director5.2yrsUS$8.55m0.27%
$ 9.7m
George Migausky
Independent Director5.2yrsUS$291.32k0.023%
$ 815.4k
Andrew Fromkin
Director5.3yrsUS$445.00k0.011%
$ 373.2k
Atul Pande
Independent Director5.3yrsUS$287.62k0.012%
$ 418.3k
Douglas Hughes
Independent Director5.2yrsUS$436.30k0.0076%
$ 268.1k
Eric Venker
Director5yrsUS$55.00kno data

5.2yrs

Average Tenure

57yo

Average Age

Experienced Board: IMVT's board of directors are considered experienced (5.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/05 23:19
End of Day Share Price 2025/02/05 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Immunovant, Inc. is covered by 17 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Jason Matthew GerberryBofA Global Research
Louise ChenCantor Fitzgerald & Co.